Exelixis Inc, a prominent biopharmaceutical firm, is dedicated to discovering, developing, and commercializing innovative cancer treatments. Their groundbreaking molecule, cabozantinib, has shown promising results in the treatment of metastatic medullary thyroid cancer (Cometriq), kidney, and liver cancer (Cabometyx). Additionally, in collaboration with Roche, Exelixis has introduced Cotellic for melanoma treatment.
In the last quarter, 20 financial analysts have shared their assessments of Exelixis, offering a diverse range of perspectives from optimistic to cautious. These insights include a detailed analysis of 12-month price targets, revealing an average target of $47.75, with a high estimate of $60.00 and a low estimate of $38.00. Notably, the current average target reflects a 10.02% increase from the previous average of $43.40. Dive deeper into Exelixis’s market position by exploring analyst evaluations in conjunction with relevant financial indicators to make informed decisions and grasp the company’s trajectory in the competitive biotech landscape.
Read more from benzinga.com